Tafamidis clinches top spot in ATTR-CM treatment
With its recent approval in Singapore, tafamidis (Vyndamax®) made headway as the first disease-modifying therapy for transthyretin amyloid cardiomyopathy (ATTR-CM), a devastating disease with a formidable symptom burden and an average survival of 2–5 years from diagnosis.
